October 2nd 2018
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.
August 22nd 2018
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.
August 6th 2018
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the entrance of biosimilars into the field of oncology.
August 1st 2018
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.
July 13th 2018
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.
January 23rd 2018
Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.
May 28th 2017
Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.
March 16th 2017
Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.
December 13th 2013
Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.
August 27th 2013
Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.
May 9th 2012
Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy
March 27th 2012
Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity
September 26th 2011
Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment
September 14th 2011
Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms
September 6th 2011
Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67
August 31st 2011
Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker
August 26th 2011
Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway
August 24th 2011
Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67